Table 3.
The 3-year survival rates of locally advanced NPC patients with different GTV-P and T categories
| Variable | OS (%) | P value | LRFS (%) | P value | DMFS (%) | P value | DFS (%) | P value |
|---|---|---|---|---|---|---|---|---|
| GTV-P (mL) | <0.001 | 0.015 | <0.001 | <0.001 | ||||
| ≤46.4 | 90.5 | 96.6 | 90.2 | 85.3 | ||||
| >46.4 | 75.5 | 90.9 | 74.5 | 67.5 | ||||
| T category | 0.105 | 0.667 | 0.035 | 0.033 | ||||
| T3 | 89.6 | 93.2 | 93.2 | 88.1 | ||||
| T4 | 83.7 | 94.7 | 82.8 | 76.4 | ||||
| Sub-T3a | 0.345 | 0.158 | ||||||
| T3V1 | 90.7 | 94.5 | 94.5 | 89.1 | ||||
| T3V2 | 75.0 | 75.0 | 75.0 | 75.0 | ||||
| Sub-T4b | <0.001 | 0.014 | <0.001 | <0.001 | ||||
| T4V1 | 90.4 | 97.2 | 89.4 | 84.0 | ||||
| T4V2 | 75.6 | 91.5 | 74.5 | 67.3 |
OS overall survival, LRFS local relapse-free survival, DMFS distant metastasis-free survival, DFS disease-free survival
aT3 tumors were subclassified as T3V1 (T3 tumors with GTV-P ≤46.4 mL) and T3V2 tumors (T3 tumors with GTV-P >46.4 mL)
bT4 tumors were subclassified as T4V1 (T4 tumors with GTV-P ≤46.4 mL) and T4V2 tumors (T4 tumors with GTV-P >46.4 mL)